Clinical Trials Browser

Interventional × Cholangiocarcinoma × camrelizumab × Clear all

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04299581 2025-02-27

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Cholangiocarcinoma

NCT04454905 2023-04-19

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Phase 2 Unknown

Gastrointestinal

Cholangiocarcinoma

NCT05697237 2023-01-25

Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma

Phase NA Unknown

Gastrointestinal

Cholangiocarcinoma

NCT04642664 2021-06-03

ACABC

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma